|AHFS/Drugs.com||International Drug Names|
|Bioavailability||High (Tmax = 2–3 hours)|
|Onset of action||1–1.5 hours|
|Excretion||Biliary (95%), renal (5%)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||527.634 g/mol g·mol−1|
|3D model (JSmol)|
Gliquidone (INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
- Allergy to sulfonylureas or sulfonamides
- Diabetes mellitus type 1
- Diabetic ketoacidosis
- Patients that underwent removal of the pancreas
- Acute porphyria
- Severe liver disease accompanying with liver insufficiency
- Several conditions (e.g., infectious diseases or major surgical intervention), when insulin administration is required
- Pregnancy or breastfeeding
Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients suffering from kidney disease and diabetic nephropathy.
- "Glurenorm (gliquidone) 30 mg Tablets, for Oral Use. Full Prescribing Information". Russian State Register of Medicinal Products (in Russian). Boehringer Ingelheim. Archived from the original on 14 August 2016. Retrieved 12 July 2016.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|